Back to Journals » The Application of Clinical Genetics » Volume 14

Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension

Authors Egom EE, Moyou-Somo R, Essame Oyono JL, Kamgang R

Received 5 October 2020

Accepted for publication 18 February 2021

Published 11 March 2021 Volume 2021:14 Pages 113—124

DOI https://doi.org/10.2147/TACG.S260755

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Martin H. Maurer


Emmanuel Eroume-A Egom,1– 3 Roger Moyou-Somo,2 Jean Louis Essame Oyono,2 Rene Kamgang2

1Institut du Savoir Montfort (ISM), Hôpital Montfort, Ottawa, ON, Canada; 2Laboratory of Endocrinology and Radioisotopes, Institute of Medical Research and Medicinal Plants Studies (IMPM), Yaoundé, Cameroon; 3Reflex Medical Centre Cardiac Diagnostics, Reflex Medical Centre, Mississauga, ON, Canada

Correspondence: Emmanuel Eroume-A Egom
Institut du Savoir Montfort (ISM), Hôpital Montfort, 713 Montreal Rd, Ottawa, ON, K1K 0T2, Canada
Email [email protected]

Abstract: Pulmonary Arterial Hypertension (PAH) is a progressive and devastating disease for which there is an escalating body of genetic and related pathophysiological information on disease pathobiology. Nevertheless, the success to date in identifying susceptibility genes, genetic variants and epigenetic processes has been limited due to PAH clinical multi-faceted variations. A number of germline gene candidates have been proposed but demonstrating consistently the association with PAH has been problematic, at least partly due to the reduced penetrance and variable expressivity. Although the data for bone morphogenetic protein receptor type 2 (BMPR2) and related genes remains undoubtedly the most extensive, recent advanced gene sequencing technologies have facilitated the discovery of further gene candidates with mutations among those with and without familial forms of PAH. An in depth understanding of the multitude of biologic variations associated with PAH may provide novel opportunities for therapeutic intervention in the coming years. This knowledge will irrevocably provide the opportunity for improved patient and family counseling as well as improved PAH diagnosis, risk assessment, and personalized treatment.

Keywords: PAH, pulmonary arterial hypertension, genes, mutations, BMPR2, bone morphogenetic protein receptor type 2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]